secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001714899-24-000120
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Q1 net loss $101.8M, cash $1.43B; reports pipeline progress and $500M PIPE
--------------------------------------------------------------------------------

- Net loss $101.8M vs $109.8M YoY; zero collaboration revenue vs $35.1M in Q1 2023.
- R&D expense $107.0M, down from $128.8M; G&A $25.2M, down from $27.1M.
- Completed $500M PIPE financing in February; raised cash to $1.43B.
- Tividenofusp alfa (MPS II) shows sustained biomarker normalization; FDA may consider accelerated path.
- Phase 1/2 for DNL126 (MPS IIIA) dosed; Phase 2/3 COMPASS enrollment expected to complete in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000120/0001714899-24-000120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000120/dnli-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001714899-24-000120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer